Show Summary Details
Page of

Pharmacological management: Disease-modifying drugs 

Pharmacological management: Disease-modifying drugs
Chapter:
Pharmacological management: Disease-modifying drugs
DOI:
10.1093/med/9780198831426.003.0016
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 09 May 2021

This chapter aims to provide a succinct overview of the key drug therapies used in the treatment of musculoskeletal conditions. It chiefly focuses on those long-term musculoskeletal conditions that require regular medications to modify the disease process. Disease-modifying drug therapies are discussed in a number of categories: conventional disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs, and then the newer targeted synthetic biologic therapies. In addition, there are therapies used in rheumatology departments such as treatments for osteoporosis and drugs prescribed to manage the pain or offer additional disease control (such as steroid therapies). Essential elements that nurses in all care sectors should be aware of, and many be instrumental in preparing for patients to receive their treatment, include the screening required, preparation prior to treatment, and follow-up monitoring and observation of potential side effects.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.